STOCK TITAN
  1. Home
  2. News
  3. IMCR

Immunocore Holdings plc American Depositary Shares - IMCR STOCK NEWS

Welcome to our dedicated page for Immunocore Holdings plc American Depositary Shares news (Ticker: IMCR), a resource for investors and traders seeking the latest updates and insights on Immunocore Holdings plc American Depositary Shares stock.

Immunocore Holdings plc (NASDAQ: IMCR) is a leading biotechnology company at the forefront of developing groundbreaking T cell receptor (TCR) bispecific immunotherapies. Leveraging its world-class TCR technology, Immunocore aims to harness the body's immune system to target and destroy diseased cells. The company's proprietary platform, known as ImmTAC (Immune mobilizing monoclonal TCRs Against Cancer), is designed to treat a variety of serious conditions, including cancer, infectious diseases, and autoimmune disorders.

Based in the United Kingdom, Immunocore has a significant presence in the United States, where the majority of its revenue is generated. The company's most notable product, KIMMTRAK® (tebentafusp-tebn), is the first approved TCR therapy for metastatic uveal melanoma, available in the United States, European Union, Canada, Australia, and the United Kingdom.

In recent news, Immunocore has entered into a clinical trial collaboration with Bristol Myers Squibb to investigate IMC-F106C, an ImmTAC bispecific TCR candidate, in combination with nivolumab for treating advanced cutaneous melanoma. This Phase 3 trial aims to assess the efficacy and safety of this combination therapy.

Immunocore's robust pipeline includes several clinical-stage programs in oncology and infectious diseases. Notable developments include ongoing trials for IMC-I109V for Hepatitis B Virus (HBV) and advanced pre-clinical programs in autoimmune diseases. Additionally, the company is expanding its PRAME ImmTAC franchise with two new candidates, IMC-P115C and IMC-T119C, targeting solid tumors.

Financially, Immunocore has successfully transitioned from a research-focused organization to a revenue-generating entity. The company's collaborative efforts with partners like DELFI Diagnostics aim to enhance cancer therapy monitoring through innovative liquid biopsy assays.

Immunocore continues to pioneer in the field of immunotherapy, with a mission to deliver transformative treatments that radically improve patient outcomes.

News

Immunocore reports fourth quarter and full year 2023 financial results and provides a business update

Rhea-AI Summary
Immunocore reports strong financial results for Q4 and full year 2023, with net revenues of $67.6 million in Q4 and $238.7 million in 2023 from KIMMTRAK sales. The company is expanding commercial access to KIMMTRAK globally and initiating registrational trials in melanoma. Clinical trial collaborations with Bristol Myers Squibb and upcoming data readouts for various programs show promising growth prospects. Immunocore's financials indicate increased net sales and R&D expenses, with a net loss of $55.3 million for 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.76%
Tags
earnings
-
News

Immunocore announces clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate IMC-F106C (PRAME HLA-A02) in combination with nivolumab in its registrational Phase 3 first-line advanced cutaneous melanoma trial

Rhea-AI Summary
Immunocore collaborates with Bristol Myers Squibb to evaluate IMC-F106C in combination with nivolumab for advanced melanoma treatment in a Phase 3 trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.15%
Tags
clinical trial
-
News

Immunocore to report fourth quarter and full year 2023 financial results and host call on February 28, 2024

Rhea-AI Summary
Immunocore Holdings plc (Nasdaq: IMCR) will report full year 2023 financial results on February 28, 2024. The Company aims to improve outcomes for patients with cancer, infectious diseases, and autoimmune diseases through transformative immunomodulating medicines.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.66%
Tags
conferences earnings
News

DELFI Diagnostics Announces Availability of New Fragmentome-Based Cancer Treatment Monitoring Assay

Rhea-AI Summary
DELFI Diagnostics, Inc. has announced the availability of the DELFI-Tumor Fraction (DELFI-TF) assay, a highly sensitive and inexpensive means of noninvasive measurement of tumor burden and assessing treatment response and resistance in patients with advanced cancer. The company has also entered a new research collaboration with Immunocore Holdings plc (Nasdaq: IMCR) to explore the use of the DELFI-TF cancer monitoring assay as an early predictor of benefit from treatment with ImmTAC-based therapies. The assay delivers a genome-wide measure of the proportion of cfDNA derived from a tumor and has numerous advantages, including low cost and minimal plasma requirement. The assay is also being evaluated by additional parties across the pharmaceutical industry for its potential application in advancing other healthcare discoveries.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.04%
Tags
none
-
News

Immunocore Prices Upsized Convertible Senior Notes Offering

Rhea-AI Summary
Immunocore Holdings plc (IMCR) announced the pricing of $350.0 million aggregate principal amount of 2.50% convertible senior notes due 2030 in a private offering to qualified institutional buyers. The offering was upsized from the previously announced offering of $300.0 million aggregate principal amount of convertible senior notes. The notes will mature on February 1, 2030, unless earlier converted, redeemed, or repurchased. Immunocore estimates that the net proceeds from the offering will be approximately $338.4 million (or approximately $389.3 million if the initial purchasers exercise their option to purchase additional notes in full), after deducting the initial purchasers’ discounts and commissions and estimated offering expenses payable by Immunocore. Immunocore intends to use the net proceeds from the offering, together with its existing cash and cash equivalents, to accelerate its clinical pipeline and for ongoing commercial expansion.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.87%
Tags
none
-
News

Immunocore Announces Proposed Convertible Senior Notes Offering

Rhea-AI Summary
Immunocore Holdings plc (Nasdaq: IMCR) announced its intention to offer $300.0 million aggregate principal amount of convertible senior notes due 2030 in a private offering to qualified institutional buyers. The notes will be senior, unsecured obligations and will accrue interest payable semi-annually in arrears. Immunocore plans to use the net proceeds to accelerate its clinical pipeline and for ongoing commercial expansion, as well as to repay loans outstanding under its loan agreement with investment funds managed by Pharmakon Advisors, LP.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.19%
Tags
none
News

Immunocore announces strategic priorities and pipeline expansion ahead of 42nd Annual J.P. Morgan Healthcare Conference presentation

Rhea-AI Summary
Immunocore Holdings plc (Nasdaq: IMCR) announces strategic priorities and pipeline expansion, including KIMMTRAK global commercial access, two registrational trials, multiple clinical readouts, and new autoimmune disease candidates. Preliminary unaudited cash and cash equivalents are approximately $443 million USD as of December 31, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.48%
Tags
none
-
News

Immunocore to present at the 42nd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary
Immunocore Holdings plc (Nasdaq: IMCR) to present at the 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.2%
Tags
conferences
-
News

Immunocore Reports Third Quarter 2023 Financial Results and Provides Business Update

Rhea-AI Summary
Immunocore reported KIMMTRAK net revenues of £49.7 million ($60.7 million) in Q3 2023, and a cash and cash equivalents increase to £364 million ($445 million) as of September 30, 2023. The company is progressing with Phase 3 clinical trials, with long-term survival for KIMMTRAK in metastatic uveal melanoma demonstrated, and expects data in multiple tumors in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.71%
Tags
earnings
News

Immunocore announces upcoming poster presentations at SITC Annual Meeting 2023 and SMR Congress 2023

Rhea-AI Summary
Immunocore Holdings plc will present data for KIMMTRAK in metastatic uveal melanoma and cutaneous melanoma at two scientific conferences. The company will present seven posters showcasing the results of various trials and studies related to tebentafusp, their novel TCR bispecific immunotherapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.56%
Tags
none

FAQ

What is the current stock price of Immunocore Holdings plc American Depositary Shares (IMCR)?

The current stock price of Immunocore Holdings plc American Depositary Shares (IMCR) is $28.325 as of December 20, 2024.

What is the market cap of Immunocore Holdings plc American Depositary Shares (IMCR)?

The market cap of Immunocore Holdings plc American Depositary Shares (IMCR) is approximately 1.4B.

What does Immunocore Holdings plc do?

Immunocore Holdings plc is a biotechnology company developing T cell receptor bispecific immunotherapies to treat cancer, infectious, and autoimmune diseases.

What is the proprietary platform of Immunocore?

Immunocore's proprietary platform is called ImmTAC, which stands for Immune mobilizing monoclonal TCRs Against Cancer.

What is KIMMTRAK?

KIMMTRAK (tebentafusp-tebn) is the first approved TCR therapy for metastatic uveal melanoma and is available in several regions including the US and EU.

Where does Immunocore generate most of its revenue?

The majority of Immunocore's revenue comes from the United States.

What recent collaboration has Immunocore entered into?

Immunocore has entered into a clinical trial collaboration with Bristol Myers Squibb to investigate IMC-F106C in combination with nivolumab for advanced cutaneous melanoma.

What are some of the clinical-stage programs Immunocore is working on?

Immunocore is working on several clinical-stage programs in oncology and infectious diseases, including IMC-I109V for HBV.

What are PRAME ImmTAC candidates?

PRAME ImmTAC candidates like IMC-P115C and IMC-T119C target solid tumors and are part of Immunocore’s portfolio expansion for treating cancer.

What is the mission of Immunocore?

Immunocore's mission is to pioneer transformative treatments that radically improve outcomes for patients with serious diseases.

How has Immunocore evolved financially?

Immunocore has evolved from a research-oriented organization to a revenue-generating company with a sustainable business model.

What role does DELFI Diagnostics play in Immunocore's research?

DELFI Diagnostics collaborates with Immunocore to enhance cancer therapy monitoring through innovative liquid biopsy assays.

Stock IMCR logo
Immunocore Holdings plc American Depositary Shares

Nasdaq:IMCR

IMCR Rankings

#2237 Ranked by Market Cap
N/A Ranked by Dividends

IMCR Stock Data

1.44B
45.35M
5.24%
94.61%
15.2%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
OXFORDSHIRE